Patents by Inventor Jane Trepel

Jane Trepel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACODYNAMIC ASSAYS
    Publication number: 20170176413
    Abstract: The present disclosure provides a method of monitoring total protein acetylation in a cell exposed to an HDAC inhibitor that involves first contacting a cell that has been exposed to an HDAC inhibitor with a plurality of reagents that each recognize and bind to a nuclear or cytoplasmic acetylated protein. The bound reagent is then detected using a detection assay and the level of the detected bound reagent is compared to a control, thereby monitoring total protein acetylation in the cell.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 22, 2017
    Inventors: Eun J. Chung, Jane Trepel
  • Pharmacodynamic assays
    Patent number: 9389223
    Abstract: The invention provides methods for quickly and easily screening mixed cell samples for a pharmacodynamic effect to a drug or test agent.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: July 12, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Jane Trepel, Eun Joo Chung
  • Modulating mxa expression
    Publication number: 20100041617
    Abstract: The invention provides compositions and methods for inhibiting cell motility, metastatic cancer and viral infections in a mammal that involve increasing the activity or expression of MxA.
    Type: Application
    Filed: September 27, 2005
    Publication date: February 18, 2010
    Inventors: Jane Trepel, Alexandra Lin, Sunmin Lee, Chand Khanna, Min-Jung Lee, Eun J. Chung, Ruilli Huang, David G. Covell
  • USE OF Mx GTPASES IN THE PROGNOSIS AND TREATMENT OF CANCER
    Publication number: 20070275401
    Abstract: The invention provides a method of reducing cancer progression comprising administering a Mx polypeptide or Mx-encoding nucleic acid to a host, such that the growth rate of the cancer cells is reduced, the metastatic potential of the cancer cells is reduced, or both. The invention also provides a method of assessing the metastatic potential of a cancer comprising (a) obtaining a sample of the cancer, (b) determining the level of Mx, Mx-nucleic acid, or both in the sample, and (c) comparing the level of Mx, Mx-encoding nucleic acid, or both with a control.
    Type: Application
    Filed: July 23, 2007
    Publication date: November 29, 2007
    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEP
    Inventors: J. Frederic Mushinski, Jane Trepel, Michel Horisberger, Phuongmai Nguyen, Chand Khanna
  • PHARMACODYNAMIC ASSAYS
    Publication number: 20070054260
    Abstract: The invention provides methods for quickly and easily screening mixed cell samples for a pharmacodynamic effect to a drug or test agent.
    Type: Application
    Filed: August 24, 2006
    Publication date: March 8, 2007
    Inventors: Jane Trepel, Eun Chung
  • Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
    Patent number: 6040334
    Abstract: Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: March 21, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Charles Myers, Jane Trepel, Won Ki Kang, Luke Whitesell, Len Neckers
  • Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
    Patent number: 5602184
    Abstract: The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: February 11, 1997
    Assignee: The United States of America as represented by Department of Health and Human Services
    Inventors: Charles E. Myers, Jane Trepel, Edward Sausville, Dvorit Samid, Alexandra Miller, Gregory Curt